Streszczenie

1. American College of Obstetrics and Gynecology: ACOG practice bulletin: premenstrual syndrome. Washington, DC: ACOG, April 2000: 15. 2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, D.C.: American Psychiatric Association,1994. 3. Bäckström T., Andreen L., Birzniece V. et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003; 17: 325-342. 4. Hussain SY, Massil JH, Matta WH et al. Buserilin in premenstrual syndrome. J Gynaecol Endocrinol 1992; 57-64. 5. Hammarback S., Backstrom T., Holst J. et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal replacement treatment. Acta Obstet Gynecol Scand 1985; 64: 393-397. 6. Halbreich U., Borenstein J., Pearlstein Tet al. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 (Supplement 3): 1-23. 7. Dickerson LM, Mazyck PJ & Hunter MH. Premenstrual syndrome. Am Fam Physician 2003; 67: 1743-1752.  8. Brambilla P., Perez J., Barale F. et al. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003; 8: 721-737. 715. 9. Rapkin AJ, Morgan M., Goldman L. et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709-714. 10. Miczek KA, Fish EW & De Bold JF. Neurosteroids, GABA receptors, and escalated aggressive behaviour. Horm Behav 2003; 44: 242-257. 11. Daugherty JE. Treatment strategies for premenstrua syndrome. Am Fam Physician 1998; 58:183-92,197-8. 12. Moline ML, Zendell SM. Evaluating and managing premenstrual syndrome. Medscape Womens Health 2000; 5: 1-16. 13, Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155:1234-40. 14. Yonkers KA, O’Brien PMS, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10. 15. Dean BB, Borenstein JE, Knight K., Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt). 2006 ;15(5):546-55. 16. Wittchen HU, Becker E., Lieb R., Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.   17. Magdy Hassan Balaha1&, Mostafa Abd El Monem Amr, Mohammed Saleh Al Moghannum, Nouria Saab Al Muhaidab. The phenomenology of premenstrual syndrome in female medical students: a cross sectional study. Nutrition Research and Practice (Nutr Res Pract)  2010; 4 (4): 290-294. 18. World Health Organization. A cross-cultural study of menstruation: implications for contraceptive development and use. Studies in Family Planning. 1981; 12: 3-16. 19. Ismail KMK, Crome I & O’Brien PMS. Psychological Disorders in Obstetrics and Gynaecology for the MRCOG and Beyond. London: RCOG Press, 2006: 29-40. 20. Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993; 29: 193-200. 21. Jarvis CI, Lynch AM, Morin AK. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann Pharmacother 2008; 42(7): 967-78. 22. Lori M. Dickerson, Pharm. D., Pamela J. Mazyck, Pharm  D. and Melissa H. Hunter, M.D. Premenstrual Syndrome. American Famyly Phiscian 2003 ; 67(8): 1743-52.  23. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Premenstrual syndrome. Obstet Gynecol 2000;95:1-9. 24. Prior JC, Vigna Y., Alojada N. Conditioning exercise decreases premenstrual symptoms. A prospective controlled three month trial. Eur J Appl Physiol 1986; 55: 349-355. 25. Prior JC, Vigna Y., Sciarretta D., et al. Conditioning exercise decreases premenstrual symptoms: a prospective controlled 6-month trial. Fertil Steril1987; 47(3): 402-408. 26. Wyatt K., Dimmock PW, O’Brien PM. Premenstrual syndrome. In: Barton S, ed. Clinical evidence. 4th  issue. London: BMJ Publishing Group, 2000: 1121-33. 27. Blake F., Salkovskis P., Gath D., Day A., Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998; 45:307-18. 28. Backstrom T., Andreen L., Birzniece V. et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003; 17: 325-342. 29. Nirav R. Shah, MD, MPH, J. B. Jones, MBA, Jaclyn Aperi, MA, Rachel Shemtov, MD, Anita Karne, MD, MSc, and Jeff Borenstein, MD, MPH. Selective Serotonin Reuptake Inhibitors for Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Meta-Analysis. Obstet Gynecol. 2008 May; 111(5): 1175-1182. 30. Steiner M., Steinberg S., Stewart D., et al. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl J Med 1995; 332:1529-1534. 31. Kornstein S., Pearlstein T., Farfel G., et al. Efficacy of sertraline in the treatment of premenstrual syndrome [poster]. Presented at the 41st annual meeting of the New Clinical Drug Evaluation Unit; 2001. 32. Halbreich U., Bergeron R., Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100: 1219-1229. 33. Wyatt KM, Dimmock PW, Ismail KMK et al. The effectiveness of GnRHa with or without‘addback’ therapy in treating premenstrual syndrome: a meta-analysis. Br. J Obstet Gynaecol 2004; 111: 585-593.  34. Freeman EW, Kroll R., Rapkin A. et al.Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.J Womens Health Gend Based Med 2001; 10: 561-569. 35. Rapkin A.. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28(Supplement 3): 39-53. 36. Hahn PM, Van Vat DA & Reid RL. A randomised, placebo-controlled crossover trail of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20: 193-209. 37. Halbriech U., Rojansky N. & Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndrome. Fertil Steril 1991; 56: 1066-1069. 38. Wetzig NR. Mastalgia: a 3-year Australian study. Aust NZJ Surg 1994; 64: 329-331.  39. O’Brien PMS & Aukhalil IED. Randonised controlled trial of management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 1999; 180: 18-23.  40. Magill PJ. Investigations of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Br J Gen Pract 1995; 45: 589-593. 41. Veneslow W., Dennerstein L., Greenwood KM et al. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J. Psychosom  Obstet Gynaecol 1996; 17: 29-38. 42. Ford O., Lethaby A., Mol B. et al. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2006; 4: CD003415. 43. Wyatt K., Dimmock P., Jones P. et al. Efficacy of progesterone and progestogens in the management of premenstrual syndrome: systematic review. BMJ 2001; 323: 776-80. 44. Aslaksen K. & Falk V. Spironolactone in the treatment of premenstrual tension:a double-blind study of spironolactone versus bendroflumethiaxide and placebo. Curr Ther Res 1991; 49: 120-130. 45. Burnet RB, Radden HS, Easterbrook EG et al. Premenstrual syndrome and spironolactone. Aust NZJ  Obstet Gynaecol 1991; 31: 366-368.  46. Berger CP, Presser B. Alprazolam in treatment of subsamples of patients with late luteal phase disorder: double-blind, placebo-controlled crossover study. Obstet Gynecol 1994; 84: 379-385. 47. Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998; 62:63-67. 48. Kaleli S., Aydin Y., Erel CT et al. Symptomatic treatment of premenstrual mastalgia in premenstrual women with lisuride maleate: a double-blind placebo-controlled randomised study. Ferttil Steril 2001;75: 718-723. 49. Ylostalo P., Kauppila A., Puolakka J. et al. Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 1981; 58: 292-298. 50. Meden-Vrtovec H. & Vujic D. Bromocriptine (Bromergon, Lek) in the management of premenstrual syndrome. Clin Exp Obstet Gynecol 1992; 19: 242-248.   51. Thys-Jacobs S., Starkey P., Bernstein D. et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual  and menstrual symptoms. Premenstrual Syndrome Study Group.  Am J Obstet Gynecol  1998; 179: 444-452. 52. Wyatt KM, Dimmock PW, Jones PW, O’Brien PM. Efficacy of vitamin B6  in the treatment of premenstrual syndrome: systematic review. BMJ Publishing Group 1999; 318: 1375-81. 53. Panay N. Managing premenstrual syndrome. Women’s Health Medicine 2005; 2: 1-4. 54. Yonkers KA, O’Brien S., Eriksson E. Premenstrual syndrome. Lancet 2008; 371: 1200-10. 55. Mi-Sook and Gun-Hee Kim. Effects of Elsholtzia splendens and Cirsium japonicum on premenstrual syndrome. Nutrition Research and Practice (Nutr Res Pract) 2010; 4(4): 290-294. 56. Girman A., Lee R., Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol. 2003 May;188(5 Suppl):S56-65.  57. Freeman EW. Therapeutic managment of premenstrual syndrome.Opin Pharmacother. 2010 Dec;11(17):2879-89.  58. Ma L., Lin S., Chen R., Zhang Y., Chen F., Wang X. Aust N Z J. Evaluating therapeutic effect in symptoms of moderate -to-severe premenstrual syndrome with Vitex agnus(BNO1095)in Chinese women. Obstet Gynaecol. 2010 Apr;50(2):189-9. 59. Döll M. The premenstrual syndrome:effectiveness of Vitex  agnus castus. Med Monatsschr Pharm. 2009 May;32(5):186-91.